The company is facing securities class action lawsuits and a federal investigation after the FDA issued a Complete Response Letter rejecting its drug relacorilant for Cushing's syndrome. Plaintiffs allege the company misrepresented regulatory communications and the drug's approval prospects. This has increased legal and regulatory scrutiny. The stock has been highly volatile, with a sharp 40.2% decline over the past year, though it has seen significant gains over longer multi-year periods, putting its current valuation in focus.